What is the recommended method to increase (titrate up) prednisolone dosage for managing a myasthenia gravis flare?

Prednisolone Dose Escalation in Myasthenia Gravis Flare

For a myasthenia gravis flare, increase prednisolone to 0.5-1.5 mg/kg/day orally as a single daily dose, starting treatment immediately without gradual titration, as the urgency of controlling the flare outweighs concerns about initial exacerbation. 1

Dosing Strategy for MG Flares

Initial Dose Escalation

• Start prednisolone at 0.5 mg/kg/day for Grade 2 symptoms (mild generalized weakness interfering with activities of daily living) 1
• Escalate to 1-1.5 mg/kg/day for Grade 3-4 symptoms (limiting self-care, dysphagia, facial weakness, or respiratory muscle weakness) 1
• Administer as a single daily dose, not divided doses 2

Critical Considerations During Escalation

Risk of Initial Exacerbation:

• High-dose corticosteroids cause initial worsening in 80% of patients, with moderate-to-marked exacerbation in 57% 3
• This risk necessitates inpatient monitoring for Grade 2 patients and ICU-level care for Grade 3-4 patients 1
• The exacerbation typically occurs early in treatment but does not prevent subsequent improvement 3

Avoid Gradual "Tapering Up":

• Unlike some rheumatologic conditions where gradual dose escalation is recommended 4, MG flares require immediate full-dose treatment due to risk of respiratory compromise 1
• The evidence shows that lower initial doses result in slower and less marked improvement without preventing exacerbation 3

Adjunctive Measures During Dose Escalation

Symptomatic Treatment

• Add pyridostigmine starting at 30 mg PO three times daily, gradually increasing to maximum 120 mg four times daily as tolerated 1
• Reduce (but don't necessarily stop) anticholinesterase medication if already on it, as withholding provides no advantage 3

Fast-Acting Immunotherapy for Severe Flares

• For Grade 3-4 flares, combine steroids with IVIG (2 g/kg IV over 5 days) or plasmapheresis (5 days) 1
• Early combination with fast-acting therapy significantly improves achievement of treatment goals (OR 2.19 at 2 years) 5
• Consider rituximab if refractory to IVIG or plasmapheresis 1

Medication Review

• Immediately discontinue medications that worsen myasthenia: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics 1

Monitoring Requirements

• Pulmonary function testing with negative inspiratory force and vital capacity at baseline and frequently during treatment 1
• Daily neurologic evaluation for Grade 3-4 patients 1
• Cardiac monitoring with troponin and ECG to evaluate for concomitant myocarditis 1

Subsequent Tapering After Flare Control

• Begin steroid taper 3-4 weeks after initiation once symptoms improve 1
• Taper based on symptom improvement, not a fixed schedule 2
• The goal is to reach minimal manifestations on ≤5 mg/day prednisolone 5
• Higher cumulative steroid doses and longer treatment duration do not ensure better outcomes 6

Common Pitfalls to Avoid

Do not use gradual dose escalation as recommended for polymyalgia rheumatica or other conditions—this approach is inappropriate for MG flares where rapid disease control is essential 1

Do not delay adding fast-acting immunotherapy in severe cases; early combination therapy significantly improves outcomes 5, 6

Do not continue high-dose steroids indefinitely; prolonged high-dose therapy without achieving treatment goals indicates need for alternative immunosuppression, not higher steroid doses 5, 6